OpGen, Inc. (OPGN) News
Filter OPGN News Items
OPGN News Results
|Loading, please wait...|
OPGN News Highlights
- OPGN's 30 day story count now stands at 6.
- Over the past 15 days, OPGN's stories per day has been in a clear downtrend, falling by about 1.00 per 8 days.
- AMR, GENE and MD are the most mentioned tickers in articles about OPGN.
Latest OPGN News From Around the Web
Below are the latest news stories about Opgen Inc that investors may wish to consider to help them evaluate OPGN as an investment opportunity.
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on OpGen (OPGN – Research Report), with a price target of $4.00. The company's shares closed last Thursday at $0.91, close to its 52-week low of $0.78. According to TipRanks.com, Chen is a 5-star analyst with an average return of 19.0% and a 37.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics. Currently, the analyst consensus on OpGen is a Moderate Buy with an average price target of $4.00.
OpGen Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology
Publication demonstrates FDA cleared Acuitas AMR Gene Panel detects and differentiates a broad range of 28 AMR markers that can be associated with up to 9 antimicrobial classes Provides results at least a day earlier than traditional methods to guide patient management and support antibiotic stewardship and infection control programsAssociating the Acuitas AMR Gene Panel markers with “not susceptible” results from culture is a key differentiator ROCKVILLE, Md., Feb. 10, 2022 (GLOBE NEWSWIRE) --
Unyvero A30 RQ analyzer successfully completed verification and validation (V&V) testing as well as lifetime testingUnyvero A30 instruments met all V&V criteria for series-production systems ROCKVILLE, Md., Feb. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that its subsidiary Curetis has successfully met a key milestone in the developm
The US economy grew 6.9% on quarter during the last three months of previous year, up from 2.3% expansion in the prior quarter and also above market estimates of 5.5%. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform. OpGen The Trade: OpGen, Inc. (NASDAQ: OPGN ) Chief Operating Officer Johannes Bacher acquired a total of 25,000 shares at an average price of $0.85. To acquire these shares, it cost $21.2...
OpGen to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
ROCKVILLE, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today it is participating in Edison Group’s Open House Event, scheduled to take place virtually this month. The three-day event, in association with London Stock Exchange, global law firm Taylor Wessing and OpenExchange, will take place between 25th-27th January, focusing on 3
OpGen (OPGN) announces preliminary revenue for in 2021 of ~$4.3M (consensus $3.8M), compared to ~$4.2M in 2020.Preliminary revenue for Q4 2021 was ~$1.4M (consensus $0.9M), despite
Preliminary unaudited revenue for 2021 was approximately $4.3 millionMaintained strong balance sheet with $36.1 million cash as of December 31, 2021 and total capital raised in 2021 of $51.2 millionConversion of all 150,000 preferred shares into 7.5 million common shares completed by investor in December 2021 ROCKVILLE, Md., Jan. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help
OpGen Inc. (NASDAQ:OPGN) traded at $1.05 at close of the session on Monday, 12/20/21, made a downward move of -2.78% on its previous days price. Looking at the stock we see that its previous close was $1.08 and the beta (5Y monthly) reads -0.61 with the days price range being $1.02 $1.08. In terms OpGen Inc. (NASDAQ:OPGN) Slides -2.78 Percent In Recent Trade, What Can We Expect Next? Read More »
OpGen Inc. (NASDAQ:OPGN) shares, rose in value on Thursday, 12/16/21, with the stock price down by -9.84% to the previous days close as strong demand from buyers drove the stock to $1.10. Actively observing the price movement in the last trading, the stock closed the session at $1.22, falling within a range of $1.10 and OpGen Inc. (NASDAQ: OPGN) Does It Provide Stability And Growth? Read More »